TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Hematological Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Renal Function Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Comparison of intra and extra cerebral metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantification of Bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aripiprazole concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quetiapine concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Olanzapine concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risperidone concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Paliperidone concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of solifenacin succinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical on state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutinin Antigen Inhibition Assay Titers at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemagglutinin Antigen Inhibition Assay Titers at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak plasma concentration (Cmax) of ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hours urine excretion of calcium corrected for creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference Between Means on Yale Global Tic Severity Scale Subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-48h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax, 0-48h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in systolic/diastolic office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Emerging cases of Clostridium difficile
Endpoint domain: Adverse events/effects
Primary endpoint: International Prostate Symptom Score (IPSS) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients reaching significant hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of time to complete sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Femoral Axial Rotation With Respect to the Tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion During Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aberdeen Varicose Vein Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual-spatial working memory span
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effect measured by Crohn's Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of acute graft-versus host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: functional Magnetic Resonance Imaging (fMRI) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Episodes of Diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Radiological Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of the difference of expiratory and inspiratory TOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of moderate and major bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast Induced-Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Copeptin dosage as a severity marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: necessity for re-introduction of any immunosuppressives
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (nmol/24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: stone free rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the rapid PSA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of patients with pancreatic neoplasms
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to PrEP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain and function as measured by an Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fusion success, defined as radiographic evidence of fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance or improvement in lower extremity neurologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygenation measured by the PO2/FiO2 (P/F) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of patient being able to complete intervention of EsoCheck
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Achieving a Combined Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total WURSS-21-K score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of the test strip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: horizontal buccal bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve of Ceftaroline over the time (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Ceftaroline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraction Event Timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of disabling complications (chronic pain, numbness, groin discomfort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Atrial Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response at 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopy Mayo Score Comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in fecal calprotectin/microbiome levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of fecal occult blood test (FOBT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Asynchrony Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left and right ventricle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radioiodide accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Determination of peak concentration (Cmax) of ABT-199
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determine maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of ABT-199
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported vestibular symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of total weight gained during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intensity of thirst
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: False negative rate of sentinel node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac rehabilitation completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intra-operative performance comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Two-year Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of responders in patients treated with FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with an adverse event (AE) through day 30 (±3 days) after FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a serious adverse event (SAE) through day 30 (±3 days) after FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity and specificity of 18F-DTBZ PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endurance time (Tlim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale Total Activities of Daily Living Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With the Indicated Number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of BETASERON injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time (days) between BETASERON injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiologic Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and severity of acute rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Stinging on Instillation
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of contingency management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased confidence in help-giving behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Echo characteristic of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse event number by treatment group
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration (Cmax) of roflumilast and its major N-oxide metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve until the last quantifiable timepoint (AUC) for roflumilast and its N-oxide metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration (Tmax) of roflumilast and its major N-oxide metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on prolactin (PRL) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oocyte gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in depression and current severity of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of insomnia based on ISI
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of wound dressing changes associated with pain <30 mm on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with normal colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with presence of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with presence of interventional pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraoperatively required amount of HES
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time until fully on oral (solid) diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of baseline pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic AF or atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical evaluation of restorative resins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD rating scale IV change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BCVA OCT changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: donor sites scar outcome according to a blinded observer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: donor sites scar outcome according to a cutometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in lumbar bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean HAM-D 17-item score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hemoglobin 10~12 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Plaque Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ischemic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMR phenotype - T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMR phenotype - T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMR phenotype - Myocardial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMR phenotype - Aortic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Food intake on ad libitum meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ad libitum meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum creatinine ≥ 0.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Symptomatic hypotension during ultrafiltration
Endpoint domain: Adverse events/effects
Primary endpoint: Hoarding Rating Scale (HRS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clutter Image Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response to diet intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement with no restenosis of the venous sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck Flexor Muscular Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neck Extensor Muscular Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical Deep Flexor Muscular Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lung Function oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac biomarkers Troponin in ng/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive function MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Leads Dyspepsia Questionnaire (LDQ) Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ovarian reserve assessment reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: maximum tolerated dose of SB1518
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smad7 expression in intestinal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects experiencing dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of health outcomes resulting in emergency room visits or hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Days completed in daily diary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analogue score of post-dural puncture headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Functional MRI Metrics Ktrans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of hydroxychloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virological response (HCV-RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cosmetic outcome assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of combined SBRT and TACE therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicity of combined SBRT and TACE therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Development of a new or recurrent disease progression event
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Area Under the Curve (AUC) of Tobramycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of PRK
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy of PRK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milligrams of Diludid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse Events related to Lithium
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Needed to Obtain Significance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in laparoscopic Cholecystectomy technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time limit of first doctor consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evolution of Glucose levels in postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evolution of Insulin in postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evolution of C-peptide in postprandial state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First Occurrence of Access Site Related Ischemic or Bleeding Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and negative predictive values for identifying pelvic nodal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes